43.20
-1.75 (-3.89%)
| Previous Close | 44.95 |
| Open | 44.66 |
| Volume | 452,062 |
| Avg. Volume (3M) | 508,980 |
| Market Cap | 1,208,433,536 |
| Price / Sales | 9.95 |
| Price / Book | 114.73 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -125.70% |
| Operating Margin (TTM) | -99.16% |
| Diluted EPS (TTM) | -4.76 |
| Quarterly Revenue Growth (YOY) | 286.80% |
| Total Debt/Equity (MRQ) | 1,016.89% |
| Current Ratio (MRQ) | 8.25 |
| Operating Cash Flow (TTM) | -108.78 M |
| Levered Free Cash Flow (TTM) | -60.04 M |
| Return on Assets (TTM) | -15.14% |
| Return on Equity (TTM) | -343.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | AnaptysBio, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.63 |
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 5.09% |
| % Held by Institutions | 133.99% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 85.00 (Stifel, 96.76%) | Buy |
| Median | 72.50 (67.82%) | |
| Low | 50.00 (Truist Securities, 15.74%) | Hold |
| Average | 70.83 (63.96%) | |
| Total | 5 Buy, 1 Hold | |
| Avg. Price @ Call | 55.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 12 Mar 2026 | 75.00 (73.61%) | Buy | 55.41 |
| Truist Securities | 09 Mar 2026 | 50.00 (15.74%) | Hold | 55.41 |
| Stifel | 05 Mar 2026 | 85.00 (96.76%) | Buy | 57.28 |
| Barclays | 04 Mar 2026 | 79.00 (82.87%) | Buy | 60.55 |
| 20 Jan 2026 | 78.00 (80.56%) | Buy | 46.21 | |
| HC Wainwright & Co. | 04 Mar 2026 | 66.00 (52.78%) | Buy | 60.55 |
| UBS | 07 Jan 2026 | 70.00 (62.04%) | Buy | 45.21 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Anaptys Announces Participation at Upcoming Investor Conferences |
| 08 Jan 2026 | Announcement | Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary |
| 06 Jan 2026 | Announcement | Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 15 Dec 2025 | Announcement | Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |